Core Insights - Heng Rui Medicine achieved revenue and profit growth in Q3 2025, driven by innovation and accelerated internationalization [1][3] - The company reported a Q3 revenue of 7.427 billion yuan, a year-on-year increase of 12.72%, and a total revenue of 23.188 billion yuan for the first three quarters, up 14.85% [1][3] - Net profit for Q3 was 1.301 billion yuan, reflecting a 9.53% year-on-year growth, while the net profit attributable to shareholders for the first three quarters reached 5.751 billion yuan, up 24.50% [1][3] Financial Performance - Q3 revenue growth of 12.72% was lower than the cumulative growth rate of 14.85% for the first three quarters, indicating a slowdown in growth momentum [3] - The net profit growth rate of 9.53% in Q3 also lagged behind the overall net profit increase of 24.50% for the first three quarters [3] - Contract liabilities surged from 160 million yuan at the beginning of the year to 3.971 billion yuan by the end of the period, primarily due to increased cash from overseas licensing fees [3] Expense Structure - Sales expenses for the first three quarters amounted to 6.780 billion yuan, accounting for 29.24% of revenue, with a year-on-year growth of 10.99% [3] - Management expenses reached 2.127 billion yuan, growing by 13.48%, which exceeded the revenue growth rate [3] - R&D expenses totaled 4.945 billion yuan, maintaining a high level of investment [1][3] Innovation and Regulatory Progress - The company received a notice from the National Medical Products Administration regarding the acceptance of the marketing application for Fluorouracil capsules, aimed at treating specific types of prostate cancer [4] - Fluorouracil has already been approved for multiple indications, including certain types of ovarian and peritoneal cancers [4]

10月27日，恒瑞医药发布2025年第三季度报告。财报数据显示，公司第三季度实现营收、利润双增长。 从利润端看，Q3单季归母净利润13.01亿元，同比增长9.53%，增速同样低于前三季度24.50%的整体水平。更值得注意的是，Q3单季扣非归母净利 润13.17亿元，同比增长16.89%。 财报中最引人注目的数据无疑是合同负债从年初的1.60亿元飙升至期末的39.71亿元，单季度增加超过38亿元。公司在现金流量表附注中明确指 出，这主要来自"海外授权首付款收到的现金增加"。 Q3单季营收74.27亿元，同比增长12.72%。 前三季度实现营业收入231.88亿元，同比增长14.85%。 Q3单季净利润13亿元，同比增长9.53%。 前三季度归属于上市公司股东的净利润为57.51亿元，同比增长24.50%。 Q3增速低于前三季度 Q3单季度12.72%的营收增速明显低于前三季度14.85%的整体增速，这意味着Q1-Q2的增长更为强劲，而第三季度出现了减速迹象。 费用方面，前三季度销售费用67.80亿元，占营收比例29.24%，虽然同比增速10.99%低于营收增速，但绝对占比依然处于高位。管理费用21.27亿 元， ...

北京商报讯（记者 王寅浩 宋雨盈）10月27日，恒瑞医药发布公告称，2025年第三季度实现营业收入 74.27亿元，同比增长12.72%；归属于上市公司股东的净利润为13.01亿元，同比增长9.53%。2025年前 三季度实现营业收入231.88亿元，同比增长14.85%；归属于上市公司股东的净利润为57.51亿元，同比 增长24.5%。 ...

（文章来源：每日经济新闻） 每经AI快讯，10月27日，恒瑞医药(600276.SH)发布2025年第三季度报告，第三季度实现营业收入74.27 亿元，同比增长12.72%；归属于上市公司股东的净利润为13.01亿元，同比增长9.53%。前三季度实现营 业收入231.88亿元，同比增长14.85%；归属于上市公司股东的净利润为57.51亿元，同比增长24.50%。 ...

江苏恒瑞医药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-166 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 江苏恒瑞医药股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日发布 公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第 三季度经营成果、财务状况，公司计划于 2025 年 11 月 4 日（星期二）下午 16:00-17:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 会议召开时间：2025 年 11 月 4 日（星期二）下午 16:00-17:00 会议内容：恒瑞医药 2025 年第三季度业绩说明会 会议时间：20 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-168 江苏恒瑞医药股份有限公司 关于药品上市许可申请获受理的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）下发的《受理通知书》，公司氟唑帕利胶囊 的药品上市许可申请获国家药监局受理。现将相关情况公告如下： 一、药品的基本情况 药品名称：氟唑帕利胶囊 剂型：胶囊剂 受理号：CXHS2500129 申报阶段：上市 申请人：江苏恒瑞医药股份有限公司 AA-P 组的影像学无进展生存期取得了显著且有临床意义的改善。 三、药品的已获批适应症情况 氟唑帕利胶囊已获批多个适应症，分别为：2020 年 12 月获批用于既往经过 二线及以上化疗的伴有胚系 BRCA 突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管 癌或原发性腹膜癌患者的治疗；2021 年 6 月获批用于铂敏感的复发性上皮性卵 巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后 的 ...

Financial Performance - The company's operating revenue for Q3 2025 reached ¥7,426,888,299.87, representing a year-on-year increase of 12.72%[3] - Total profit for the period was ¥1,361,073,585.78, reflecting a growth of 1.94% compared to the same period last year[3] - Net profit attributable to shareholders was ¥1,301,063,153.19, up by 9.53% year-on-year[3] - Total operating revenue for the first three quarters of 2025 reached ¥23,188,081,928.77, an increase of 14.8% compared to ¥20,189,303,845.10 in the same period of 2024[16] - Net profit for the first three quarters of 2025 was ¥5,760,235,152.02, compared to ¥4,616,330,177.46 in 2024, marking a growth of 24.7%[17] - Earnings per share for the first three quarters of 2025 were ¥0.89, an increase from ¥0.73 in the same period of 2024[17] Cash Flow and Liquidity - The net cash flow from operating activities for the period was ¥4,809,977,038.87, a significant increase of 209.78%[3] - In the first three quarters of 2025, the net cash flow from operating activities was ¥9,110,430,290.27, a significant increase of 98.5% compared to ¥4,585,446,009.12 in the same period of 2024[20] - Cash received from the sale of goods and services reached ¥26,173,262,016.04, up 30.8% from ¥20,000,144,131.46 in the previous year[20] - The net increase in cash and cash equivalents for the period was ¥15,528,606,009.65, compared to ¥1,184,255,955.68 in the previous year, reflecting strong liquidity growth[20] - The cash and cash equivalents at the end of the period totaled ¥39,767,708,127.31, a significant rise from ¥21,455,780,225.40 at the end of the same period last year[20] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥68,327,540,485.78, marking a 36.29% increase from the previous year[4] - Total assets as of September 30, 2025, amounted to ¥68,327,540,485.78, compared to ¥50,135,645,304.10 at the end of 2024, indicating a growth of 36.2%[14] - Total liabilities increased to ¥8,295,022,482.91 from ¥4,045,394,570.79, representing a rise of 104.5%[14] Shareholder Information - The equity attributable to shareholders reached ¥59,504,250,787.19, which is a 30.72% increase compared to the end of the previous year[4] - The company reported a total of 397,258 ordinary shareholders at the end of the reporting period[10] - The largest shareholder, Jiangsu Hengrui Medicine Group Co., Ltd., holds 1,538,184,187 shares, accounting for 23.18% of the total shares[10] - The total equity attributable to shareholders of the parent company reached ¥59,504,250,787.19, up from ¥45,519,861,860.32, indicating a growth of 30.6%[14] Research and Development - Research and development expenses for the first three quarters of 2025 were ¥4,945,318,580.23, compared to ¥4,548,870,345.14 in 2024, reflecting an increase of 8.7%[16] Investment Activities - The cash outflow from investment activities was ¥1,714,462,484.69, compared to ¥2,124,667,512.24 in the previous year, showing a decrease in investment spending[20] - The company received cash from investment of ¥151,000,000.00, down from ¥200,000,000.00 in the previous year, indicating a decline in cash recovery from investments[20]

人民财讯10月27日电，恒瑞医药（600276）10月27日2025年第三季度报告，第三季度营收为74.27亿 元，同比增长12.72%；净利润为13.01亿元，同比增长9.53%。前三季度净利润为57.51亿元，同比增长 24.5%。 ...

市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何 意见、观点或结论是否符合其特定状况。据此投资，责任自负。 恒瑞医药：第三季度净利润13亿元，同比增长9.53%；前三季度净利润57.5亿元，同比增长24.50%。 风险提示及免责条款 ...

Core Viewpoint - Heng Rui Medicine (1276.HK) experienced a 5.21% increase in stock price to 80.8 HKD following the announcement of the approval for its innovative oral diabetes medication, marking a significant milestone in the Chinese pharmaceutical market [1] Company Summary - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its product, HR20031 tablets, which is the first self-developed oral combination therapy for type 2 diabetes in China [1] - The product is designed for adult patients with type 2 diabetes who have inadequate blood sugar control despite treatment with metformin [1] Industry Summary - According to a report from Galaxy Securities, the pharmaceutical sector has undergone a prolonged valuation adjustment but is now showing a significant structural recovery trend [1] - Public fund holdings in the pharmaceutical sector remain below historical averages, indicating potential for growth [1] - The policy environment supporting the development of commercial insurance is expected to lead to marginal improvements in payment systems by 2025, benefiting innovative drugs and medical devices [1] - The outlook for the pharmaceutical industry remains positive, with continued interest in innovative drug business development (BD) and a potential revival in pharmaceutical investment and financing [1]